Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464802 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects
A Phase 1 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00464802 is a Phase 1 study that has completed, run by Bausch Health Americas. The registered enrollment target is 36 participants.
The verdict
NCT00464802, a Phase 1 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety and tolerability of the new IV formulation versus the current formulation of MOA-728 focusing on the theoretical potential for infusion-related and formulation-related complications.
Interventions
- DRUG MOA-728
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464802
The ClinicalTrials.gov registry entry for NCT00464802 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MOA-728 is the first listed.
NCT00464802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464802 about?
NCT00464802 is a clinical study titled "Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects". The primary objective is to determine the safety and tolerability of the new IV formulation versus the current formulation of MOA-728 focusing on the theoretical potential for infusion-related and formulation-related complications.
What is the current status of trial NCT00464802?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-04. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00464802?
The interventions under investigation include: MOA-728 (DRUG).
Who is sponsoring clinical trial NCT00464802?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.